United Laboratories Doses First Patient in Phase 3 Trial in China of Type 2 Diabetes Drug

MT Newswires Live

Sep 08

United Laboratories International Holdings (HKG:3933) dosed its first patient in China for a phase 3 trial of UBT251, the company's proposed treatment for type 2 diabetes, according to a Monday bourse filing.

The pharmaceutical company said the late-stage study will be broken into two separate studies, UNIGUIDE-1 and UNIGUIDE-2.

Both studies have a primary endpoint of monitoring the baseline change in blood glucose levels after 40 weeks. However, UNIGUIDE-2 also includes a secondary endpoint of changes in body weight, blood pressure, and blood lipid levels, as well as the baseline change in blood glucose levels after 52 weeks.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/news/2665283349"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2665283349\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2665283349?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-08 10:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2665283349","market":"fut","top_or_hot":-1,"title":"United Laboratories Doses First Patient in Phase 3 Trial in China of Type 2 Diabetes Drug","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ULIHF\">United Laboratories</a> International Holdings (HKG:3933) dosed its first patient in China for a phase 3 trial of UBT251, the company's proposed treatment for type 2 diabetes, according to a Monday bourse filing.</p><p>The pharmaceutical company said the late-stage study will be broken into two separate studies, UNIGUIDE-1 and UNIGUIDE-2.</p><p>Both studies have a primary endpoint of monitoring the baseline change in blood glucose levels after 40 weeks. However, UNIGUIDE-2 also includes a secondary endpoint of changes in body weight, blood pressure, and blood lipid levels, as well as the baseline change in blood glucose levels after 52 weeks.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>United Laboratories Doses First Patient in Phase 3 Trial in China of Type 2 Diabetes Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnited Laboratories Doses First Patient in Phase 3 Trial in China of Type 2 Diabetes Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-08 10:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ULIHF\">United Laboratories</a> International Holdings (HKG:3933) dosed its first patient in China for a phase 3 trial of UBT251, the company's proposed treatment for type 2 diabetes, according to a Monday bourse filing.</p><p>The pharmaceutical company said the late-stage study will be broken into two separate studies, UNIGUIDE-1 and UNIGUIDE-2.</p><p>Both studies have a primary endpoint of monitoring the baseline change in blood glucose levels after 40 weeks. However, UNIGUIDE-2 also includes a secondary endpoint of changes in body weight, blood pressure, and blood lipid levels, as well as the baseline change in blood glucose levels after 52 weeks.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2665283349","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2665283349","pubTimestamp":1788836015,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"United Laboratories International Holdings  dosed its first patient in China for a phase 3 trial of UBT251, the company's proposed treatment for type 2 diabetes, according to a Monday bourse filing.The pharmaceutical company said the late-stage study will be broken into two separate studies, UNIGUIDE-1 and UNIGUIDE-2.Both studies have a primary endpoint of monitoring the baseline change in blood glucose levels after 40 weeks. However, UNIGUIDE-2 also includes a secondary endpoint of changes in body weight, blood pressure, and blood lipid levels, as well as the baseline change in blood glucose levels after 52 weeks.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药","BK4211":"区域性银行","IE00B3M56506.USD":"NEUBERGER BERMAN EMERGING MARKETS EQUITY \"A\" (USD) ACC","UBCP":"联合合众银行","BK1191":"制药"},"translate_title":"联邦制药为中国首例2型糖尿病药物3期试验患者注射","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UBCP":1.5,"03933":1},"content_text":"United Laboratories International Holdings (HKG:3933) dosed its first patient in China for a phase 3 trial of UBT251, the company's proposed treatment for type 2 diabetes, according to a Monday bourse filing.The pharmaceutical company said the late-stage study will be broken into two separate studies, UNIGUIDE-1 and UNIGUIDE-2.Both studies have a primary endpoint of monitoring the baseline change in blood glucose levels after 40 weeks. However, UNIGUIDE-2 also includes a secondary endpoint of changes in body weight, blood pressure, and blood lipid levels, as well as the baseline change in blood glucose levels after 52 weeks.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}